CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, S. P.
Right arrow Articles by Brattain, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, S. P.
Right arrow Articles by Brattain, M. G.

Cell Growth & Differentiation, Vol 4, Issue 2 115-123, Copyright © 1993 by American Association of Cancer Research


ARTICLES

Repression of autocrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties

SP Wu, LZ Sun, JK Willson, L Humphrey, R Kerbel and MG Brattain
Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo 43699-0008.

Previous work has shown that repression of negative autocrine transforming growth factor (TGF) beta 1 did not alter the growth rate of a human colon carcinoma cell line, but the time required for the cells to enter exponential growth from lag phase was reduced (S. P. Wu, D. Theodorescu, R. Kerbel, J. K. V. Willson, K. M. Mulder, L. E. Humphrey, and M. G. Brattain, J. Cell Biol., 116: 187-196, 1992). These results have led to the hypothesis that the tumor suppressive activity of autocrine TGF-beta 1 was directed at quiescent nondividing cells rather than actively dividing cells. In order to test this hypothesis, a weakly tumorigenic, well-differentiated human colon carcinoma cell line designated CBS, which expressed autocrine TGF-beta 1 and -beta 2 activity in quiescent cells, but not in exponential growth phase cells, was identified. This cell line was stably transfected with a full-length TGF-beta 1 antisense complementary DNA. Constitutive expression of TGF-beta 1 antisense mRNA in CBS cells resulted in repression of autocrine TGF-beta 1 and -beta 2 protein activity in quiescent cells of approximately 10-fold. TGF-beta 2 repression could have been due to interaction with TGF-beta 1 antisense mRNA, since these two isoforms have a high degree of homology, or it could have been indirectly due to TGF-beta 1 repression, since this isoform has been shown to affect transcriptional and posttranscriptional control of TGF-beta 2.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
J Biol ChemHome page
X.-Q. Liu, A. Rajput, L. Geng, M. Ongchin, A. Chaudhuri, and J. Wang
Restoration of Transforming Growth Factor-{beta} Receptor II Expression in Colon Cancer Cells with Microsatellite Instability Increases Metastatic Potential in Vivo
J. Biol. Chem., May 6, 2011; 286(18): 16082 - 16090.
[Abstract] [Full Text] [PDF]


Home page
Cancer Genomics ProteomicsHome page
M. PERERA, C. S. TSANG, R. J. DISTEL, J. N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L. P. SAMARANAYAKE, G. B. SMEJKAL, M. G. SMITH, A. J. TRACHTENBERG, et al.
TGF-{beta}1 Interactome: Metastasis and Beyond
Cancer Genomics Proteomics, July 1, 2010; 7(4): 217 - 229.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Wang, L. Yang, J. Yang, K. Kuropatwinski, W. Wang, X.-Q. Liu, J. Hauser, and M. G. Brattain
Transforming Growth Factor {beta} Induces Apoptosis through Repressing the Phosphoinositide 3-Kinase/AKT/Survivin Pathway in Colon Cancer Cells
Cancer Res., May 1, 2008; 68(9): 3152 - 3160.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. Wang, N. Sergina, T. C. Ko, J. Gong, and M. G. Brattain
Autocrine and Exogenous Transforming Growth Factor {beta} Control Cell Cycle Inhibition through Pathways with Different Sensitivity
J. Biol. Chem., September 17, 2004; 279(38): 40237 - 40244.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ammanamanchi, M. P. M. Tillekeratne, T. C. Ko, and M. G. Brattain
Endogenous Control of Cell Cycle Progression by Autocrine Transforming Growth Factor {beta} in Breast Cancer Cells
Cancer Res., April 1, 2004; 64(7): 2509 - 2515.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Zawel, J. Yu, C. J. Torrance, S. Markowitz, K. W. Kinzler, B. Vogelstein, and S. Zhou
DEC1 is a downstream target of TGF-{beta} with sequence-specific transcriptional repressor activities
PNAS, March 5, 2002; 99(5): 2848 - 2853.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
H. Yang, S. Kyo, M. Takatura, and L. Sun
Autocrine Transforming Growth Factor {beta} Suppresses Telomerase Activity and Transcription of Human Telomerase Reverse Transcriptase in Human Cancer Cells
Cell Growth Differ., February 1, 2001; 12(2): 119 - 127.
[Abstract] [Full Text]


Home page
JCOHome page
S. Markowitz
DNA Repair Defects Inactivate Tumor Suppressor Genes and Induce Hereditary and Sporadic Colon Cancers
J. Clin. Oncol., November 1, 2000; 18(90001): 75s - 80.
[Full Text] [PDF]


Home page
Cancer Res.Home page
S.-C. Ye, J. M. Foster, W. Li, J. Liang, E. Zborowska, S. Venkateswarlu, J. Gong, M. G. Brattain, and J. K. V. Willson
Contextual Effects of Transforming Growth Factor {beta} on the Tumorigenicity of Human Colon Carcinoma Cells
Cancer Res., September 1, 1999; 59(18): 4725 - 4731.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Wang, L. Sun, E. Zborowska, J. K. V. Willson, J. Gong, J. Verraraghavan, and M. G. Brattain
Control of Type II Transforming Growth Factor-{beta} Receptor Expression by Integrin Ligation
J. Biol. Chem., April 30, 1999; 274(18): 12840 - 12847.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Won, H. Kim, E. J. Park, Y. Hong, S.-J. Kim, and Y. Yun
Tumorigenicity of Mouse Thymoma Is Suppressed by Soluble Type II Transforming Growth Factor {beta} Receptor Therapy
Cancer Res., March 1, 1999; 59(6): 1273 - 1277.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Ammanamanchi, S.-J. Kim, L.-Z. Sun, and M. G. Brattain
Induction of Transforming Growth Factor-{beta} Receptor Type II Expression in Estrogen Receptor-positive Breast Cancer Cells through SP1 Activation by 5-Aza-2'-deoxycytidine
J. Biol. Chem., June 26, 1998; 273(26): 16527 - 16534.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
G. Wu, R. S. Fan, W. Li, V. Srinivas, and M. G. Brattain
Regulation of Transforming Growth Factor-{beta} Type II Receptor Expression in Human Breast Cancer MCF-7 Cells by Vitamin D3and Its Analogues
J. Biol. Chem., March 27, 1998; 273(13): 7749 - 7756.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Zhou, P. Buckhaults, L. Zawel, F. Bunz, G. Riggins, J. Le Dai, S. E. Kern, K. W. Kinzler, and B. Vogelstein
Targeted deletion of Smad4 shows it is required for transforming growth factor {beta} and activin signaling in colorectal cancer cells
PNAS, March 3, 1998; 95(5): 2412 - 2416.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. Sun and C. Chen
Expression of Transforming Growth Factor {beta} Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells
J. Biol. Chem., October 3, 1997; 272(40): 25367 - 25372.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
C. Chen, X.-F. Wang, and L. Sun
Expression of Transforming Growth Factor {beta} (TGF{beta}) Type III Receptor Restores Autocrine TGF{beta}1 Activity in Human Breast Cancer MCF-7 Cells
J. Biol. Chem., May 9, 1997; 272(19): 12862 - 12867.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. T. Hartsough, R. S. Frey, P. A. Zipfel, A. Buard, S. J. Cook, F. McCormick, and K. M. Mulder
Altered Transforming Growth Factor {beta} Signaling in Epithelial Cells when Ras Activation Is Blocked
J. Biol. Chem., September 13, 1996; 271(37): 22368 - 22375.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. Wang, W. Han, E. Zborowska, J. Liang, X. Wang, J. K. V. Willson, L. Sun, and M. G. Brattain
Reduced Expression of Transforming Growth Factor {beta} Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells
J. Biol. Chem., July 19, 1996; 271(29): 17366 - 17371.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
J. Wang, L. Sun, L. Myeroff, X. Wang, L. E. Gentry, J. Yang, J. Liang, E. Zborowska, S. Markowitz, J. K. V. Willson, et al.
Demonstration That Mutation of the Type II Transforming Growth Factor {beta} Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells
J. Biol. Chem., September 15, 1995; 270(37): 22044 - 22049.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Wang, G.-h. Zhou, T. M. Birkenmeier, J. Gong, L. Sun, and M. G. Brattain
Autocrine Transforming Growth Factor {beta}1 Modulates the Expression of Integrin {alpha}5{beta}1 in Human Colon Carcinoma FET Cells
J. Biol. Chem., June 9, 1995; 270(23): 14154 - 14159.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
S Markowitz, J Wang, L Myeroff, R Parsons, L Sun, J Lutterbaugh, R. Fan, E Zborowska, K. Kinzler, B Vogelstein, et al.
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
Science, June 2, 1995; 268(5215): 1336 - 1338.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1993 by the American Association of Cancer Research.